SVA Sernova Corp

Sernova Corp. (TSX VENTURE:SVA), today announced that the Australian Patent
Office has issued a Notice of Acceptance to Sernova for its patent application
entitled "Methods and Devices for Cellular Transplantation." 


This patent covers Sernova's entire Cell Pouch(TM) system of therapeutic cells,
the Cell Pouch(TM) and its surgical tools for cell transplantation. The
allowance of this patent will provide Sernova with patent protection through
2030. Similar patent applications have been filed in multiple countries around
the world and have a higher likelihood of being granted now that the Australian
one has been allowed. 


"With this patent allowance, Sernova is now advancing to secure exclusive patent
rights globally of our core technologies," stated Dr. Philip Toleikis, Sernova's
President and CEO. "This patent allowance is timely as intellectual property is
a key element in attracting partners, which is the focus of our new world-class
business development team." 


"The transition of intellectual property from a patent application to an allowed
patent is a key component in strengthening the valuation of a technology", said
Kevin Egan, Chair of Sernova's Business Advisory Board. "The fact that Sernova
has achieved this for its platform technologies significantly increases its
value and potential to partner with a major pharmaceutical or medical device
company." 


When transplanted into Sernova's Cell Pouch(TM), a safe, protected and
efficacious environment is provided for therapeutic cells such as
insulin-producing islets for the treatment of diabetes, as demonstrated in
multiple preclinical studies. 


In human patients with diabetes, the Cell Pouch(TM), transplanted with insulin
producing islets, in interim analyses, has been shown to be biocompatible and
safe as the primary objective of a clinical study at the University of Alberta
with Dr. James Shapiro as principal investigator. 


Sernova is exploring the additional utility of the Cell Pouch(TM) an enabling
platform for a range of diseases such as haemophilia with Medicyte Gmbh and to
maintain calcium homeostasis in kidney disease through parathyroid gland
transplantation. 


About Sernova 

Sernova Corp is a clinical stage regenerative medicine company developing
medical technologies for the treatment of chronic debilitating metabolic
diseases such as diabetes, blood disorders including haemophilia and other
diseases treated through replacement of proteins or hormones missing or in short
supply within the body. Sernova is developing the Cell Pouch(TM), an implantable
medical device for therapeutic cells (donor, xenogeneic or stem cells) which
then release proteins and/or hormones as required. The therapeutic cells are
protected from immune attack by Sernova's proprietary local immune protection
technology.  


Forward Looking Information 

This release may contain forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not always,
identified by the words "expects", "plans", "anticipates", "believes",
"intends", "estimates", "projects", "potential" and similar expressions, or that
events or conditions "will", "would", "may", "could" or "should" occur. Although
Sernova believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from those in
forward looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of Sernova's management on the date such statements were
made. Sernova expressly disclaims any intention or obligation to update or
revise any forward-looking statements whether as a result of new information,
future events or otherwise.


Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Sernova Corp.
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
philip.toleikis@sernova.com / info@sernova.com
www.sernova.com


Ray Matthews & Associates
Suite 601-128 West Cordova Street, Vancouver, BC V6B 0E6
(604) 818-7778
www.raymatthews.ca

Sernova (TSXV:SVA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Sernova (TSXV:SVA)
Historical Stock Chart
From Feb 2024 to Feb 2025